Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Fosigotifator

Source date not recordedAnalyse record ↗

eIF2B activator in recruiting Phase 1/2 research for vanishing white matter disease after completion or termination of its ALS studies.

Modality
oral small-molecule eIF2B activator that modulates the integrated stress response
Availability (US)
Phase 1/2 vanishing-white-matter-disease study Recruiting; listed ALS studies Completed or Terminated
Biomarkers
treatment-emergent adverse events; pharmacokinetics; neurological assessments; integrated-stress-response biomarkers
Hallmark targeted
loss of proteostasis, integrated stress response, cellular stress adaptation
Kind
investigational drug
Clinical trials
NCT05757141 — Phase 1/Phase 2, Recruiting on September 24, 2026 update; NCT05740813 — Phase 2/Phase 3 ALS regimen Completed; NCT04948645 — Phase 1 ALS study Terminated